Passage Bio Executive Reshuffle and Strategic Focus Shift
Company Announcements

Passage Bio Executive Reshuffle and Strategic Focus Shift

Passage Bio (PASG) has shared an update.

Mark Forman, the Chief Medical Officer of the Company, has chosen to resign effective August 2, 2024, without any conflicts over the Company’s operations, policies, or practices. In a strategic move, the Company announced Susan Browne as the new Chief Scientific Officer and Stuart Henderson as Chief Business Officer, effective August 1, 2024. Both executives have significantly shaped the Company’s direction, with Browne enhancing the clinical portfolio and Henderson building valuable financial and business relationships, steering the focus towards researching progranulin’s role in adult neurodegenerative diseases.

See more data about PASG stock on TipRanks’ Stock Analysis page.

Related Articles
Catie PowersPASG Upcoming Earnings Report: What to Expect?
TipRanks Auto-Generated NewsdeskPassage Bio Presents Promising Data on PBFT02 Therapy
TheFlyPassage Bio delivered preclinical, interim data at ESGCT
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App